333. ハッチンソン・ギルフォード症候群 Hutchinson-Gilford syndrome Clinical trials / Disease details
臨床試験数 : 8 / 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00916747 (ClinicalTrials.gov) | August 2009 | 5/6/2009 | Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | An Open Label Phase II Trial of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Hutchinson-Gilford Progeria Syndrome(HGPS) and Progeroid Laminopathies | Progeria | Drug: Lonafarnib, Zoledronic Acid, and Pravastatin | Boston Children's Hospital | Schering-Plough;Merck Sharp & Dohme LLC;Eiger BioPharmaceuticals | Active, not recruiting | N/A | N/A | All | 85 | Phase 2 | United States |
2 | NCT00879034 (ClinicalTrials.gov) | March 2009 | 8/4/2009 | A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria | A Phase II Pilot Study of Zoledronic Acid, Pravastatin, and Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies | Progeria;Hutchinson-Gilford Syndrome | Drug: Lonafarnib;Drug: Zoledronic Acid;Drug: Pravastatin | Boston Children's Hospital | Dana-Farber Cancer Institute;Brigham and Women's Hospital;Schering-Plough | Completed | N/A | N/A | All | 5 | Phase 2 | United States |
3 | NCT00731016 (ClinicalTrials.gov) | October 2008 | 1/8/2008 | Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid | Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid | Hutchinson-Gilford Progeria Syndrome | Drug: Zoledronic acid, pravastatin | Assistance Publique Hopitaux De Marseille | NULL | Completed | 3 Years | N/A | Both | 15 | Phase 2 | France |